CPI-169

CAS No. 1450655-76-1

CPI-169( CPI-169 | CPI 169 | CPI169 )

Catalog No. M17305 CAS No. 1450655-76-1

CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 141 In Stock
2MG 68 In Stock
5MG 121 In Stock
10MG 171 In Stock
25MG 376 In Stock
50MG 548 In Stock
100MG 780 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CPI-169
  • Note
    Research use only, not for human use.
  • Brief Description
    CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
  • Description
    CPI-169 is a potent inhibitor of enhancer of zeste homolog 2 (EZH2) with an IC50 value of <1nM for polycomb repressive complex 2 (PRC2). CPI-169 was shown to inhibit tumor growth in a NHL xenograft model, reducing global H3K27me3.1 It has also been shown to synergize with the B-cell lymphoma inhibitor, ABT-199, to suppress the growth of NHL cell lines.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CPI-169 | CPI 169 | CPI169
  • Pathway
    Angiogenesis
  • Target
    ALK
  • Recptor
    EZH1| EZH2 WT| EZH2 Y641N
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1450655-76-1
  • Formula Weight
    528.66
  • Molecular Formula
    C27H36N4O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 59 mg/mL. 111.60 mM
  • SMILES
    CCS(=O)(=O)N1CCC(CC1)C(C)n1c2ccccc2c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c1C
  • Chemical Name
    (R,Z)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((2-hydroxy-4-methoxy-6-methylpyridin-3-yl)methyl)-2-methyl-1H-indole-3-carbimidic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bradley WD,etal.EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.Chem Biol. 2014 Nov 20;21(11):1463-75.
molnova catalog
related products
  • JH-VIII-157-02

    JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM.

  • CH5424802 analog

    CH5424802 analog is a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  • Iruplinalkib

    Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.